Modelling of ORL1 receptor-ligand interactions

被引:5
|
作者
Sencanski, Milan [1 ]
Ivanovic, Milovan D. [2 ,3 ]
Dosen-Micovic, Ljiljana [2 ,3 ]
机构
[1] Univ Belgrade, Fac Chem, Innovat Ctr, Belgrade 11158, Serbia
[2] Univ Belgrade, Fac Chem, Belgrade 11158, Serbia
[3] Univ Belgrade, Ctr Chem, ICTM, Belgrade 11158, Serbia
来源
CHEMICAL PAPERS | 2014年 / 68卷 / 10期
关键词
molecular modelling; ORL1; receptor; ligand-receptor interactions; docking simulation; molecular dynamics; NOCICEPTIN/ORPHANIN FQ RECEPTOR; MOLECULAR-DYNAMICS; ACTIVE STATE; AGONISTS; COMPLEX; BINDING; OPTIMIZATION; ADRENOCEPTOR; ANTAGONISTS; ACTIVATION;
D O I
10.2478/s11696-014-0577-z
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
An opioid receptor like (ORL1) receptor is one of a family of G-protein-coupled receptors (GPCR); it represents a new pharmaceutical target with extensive therapeutic potential for the regulation of important biological functions such as nociception, mood disorders, drug abuse, learning or cardiovascular control. Although the crystal structure of the inactive form of the ORL1 receptor has been determined, little is known about its activation. By using X-ray structures of the beta 2-adrenegic receptor in its inactive (2RH1) and active (3P0G) states as templates, inactive and active homology models of the ORL1 receptor were constructed. Structurally diverse sets of strongly binding antagonists and agonists were docked with both ORL1 receptor forms. The major receptor-ligand interactions responsible for antagonist and agonist binding were identified. Although both sets of ligands, agonists and antagonists, bind to the same region of the receptor, they occupy partially different binding pockets. Agonists bind to the inactive receptor in a slightly different manner than antagonists. This difference is more pronounced in binding to the active ORL1 receptor model and points to the amino acids at the extracellular end of TM6, suggesting that this region is important for receptor-activation. (C) 2014 Institute of Chemistry, Slovak Academy of Sciences
引用
收藏
页码:1305 / 1316
页数:12
相关论文
共 50 条
  • [41] Solving inconsistencies in the analysis of receptor-ligand interactions
    Tuk, B
    vanOostenbruggen, MF
    TRENDS IN PHARMACOLOGICAL SCIENCES, 1996, 17 (11) : 403 - 409
  • [42] Kinetics of Receptor-Ligand Interactions in Immune Responses
    Mian Long
    Cellular & Molecular Immunology, 2006, (02) : 79 - 86
  • [43] Mechanokinetics of receptor-ligand interactions in cell adhesion
    Li, Ning
    Lu, Shouqin
    Zhang, Yan
    Long, Mian
    ACTA MECHANICA SINICA, 2015, 31 (02) : 248 - 258
  • [44] Therapeutic vaccination to block receptor-ligand interactions
    Spohn, G
    Bachmann, MF
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2003, 3 (03) : 469 - 476
  • [45] Structural Insights into Notch Receptor-Ligand Interactions
    Handford, Penny A.
    Korona, Boguslawa
    Suckling, Richard
    Redfield, Christina
    Lea, Susan M.
    MOLECULAR MECHANISMS OF NOTCH SIGNALING, 2018, 1066 : 33 - 46
  • [46] ReLiBase - A DATABASE FOR ANALYSING RECEPTOR-LIGAND INTERACTIONS
    Hendlich, Manfred
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 1999, 55 : 71 - 71
  • [47] Induced expression of ORL1 receptor used to study signalling effects
    Bevan, NJ
    Scott, S
    Rhodes, A
    Marshall, FH
    Rees, ES
    Lee, MG
    BRITISH JOURNAL OF PHARMACOLOGY, 1998, 123
  • [48] Probing opioid receptor interactions with azacycloalkane amino acids.: Synthesis of a potent and selective ORL1 antagonist
    Halab, L
    Becker, JAJ
    Darula, Z
    Tourwé, D
    Kieffer, BL
    Simonin, F
    Lubell, WD
    JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (24) : 5353 - 5357
  • [49] Modelling of the Receptor-Ligand Interaction in a Single Cell Mode
    Stepanov, A. V.
    Xie, J.
    Dronina, M. A.
    Knorre, V. D.
    Belogurov, A. A., Jr.
    Deyev, S. M.
    Gabibov, A. G.
    BIOLOGICHESKIE MEMBRANY, 2015, 32 (02): : 102 - 109
  • [50] Upregulation of the ORL1 receptor in mice lacking the orphanin FQ peptide gene
    Clarke, S
    Chen, Z
    Hsu, MS
    Pintar, J
    Hill, RG
    Kitchen, I
    BRITISH JOURNAL OF PHARMACOLOGY, 2000, 129 : U25 - U25